IVX
INVION LIMITED
$0.0370
▲ +12.12%
Market cap
$4M
Turnover
$555
Last price
$0.0370
Day change
+12.12%
Announcements
9
Range, past year
Open 0.076 · Low 0.032 · Now 0.037 · High 0.200
Open IVX in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
IVX momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-11-16.
Momentum quality
23/100
Wyckoff phase
Accumulation1d
Trend stage
Neutral
1 Day
+12.1%
1 Week
+8.8%
1 Month
+8.8%
1 Year
-53.8%
RSI
53
Avg daily range
6.6%
INVION LIMITED scores 23 out of 100 for momentum quality, a reading rated very low confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Neutral.
On the Wyckoff cycle it sits in Accumulation, where it has been for 1 trading day. The weekly timeframe reads Downtrend, which does not yet agree with the daily view.
Against the wider market it is currently matching and the institutional accumulation signal reads low.
Points to watch
- 60d drawdown -28.9%
- High volatility (ATR 6.6%)
- Thin liquidity
- Risk rating: Very High
- Composite downside risk elevated
IVX announcements
Recent price-sensitive releases.
- 2026-10-29 Appendix 4C and Quarterly Activities Report - September 2026 Commitments Test Entity - First Quarter Activity Report | Commitments Test Entity - First Quarter Cashflow Report
- 2026-10-21 Funding Agreements Cover Up to 85% of Clinical Trials Costs Progress Report | Debt Facility
- 2026-10-19 Recruitment Conclusion for Ph 1 NMSC Trial & Advance to Ph 2 Progress Report
- 2026-08-26 Appendix 4E and Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-31 Appendix 4C and Quarterly Activities Report - June 2026 Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-05-19 Photosoft Platform Expands to Eye Diseases Via Partnership
- 2026-04-30 Appendix 4C and Quarterly Activities Report - March 2026
More Health Care stocks
Most traded in the same sector.